131 related articles for article (PubMed ID: 8601221)
21. Viral load, CD4 percentage, and delayed-type hypersensitivity in subjects receiving the HIV-1 immunogen and antiviral drug therapy.
Moss RB; Ferre F; Levine A; Turner J; Jensen FC; Daigle AE; Richieri SP; Truckenbrod A; Trauger RJ; Carlo DJ; Salk J
J Clin Immunol; 1996 Sep; 16(5):266-71. PubMed ID: 8886995
[TBL] [Abstract][Full Text] [Related]
22. Phase I trial of a therapeutic HIV type 1 vaccine, Vacc-4x, in HIV type 1-infected individuals with or without antiretroviral therapy.
Asjö B; Stavang H; Sørensen B; Baksaas I; Nyhus J; Langeland N
AIDS Res Hum Retroviruses; 2002 Dec; 18(18):1357-65. PubMed ID: 12487807
[TBL] [Abstract][Full Text] [Related]
23. Delayed-type hypersensitivity responses to HIV Gag p24 relate to clinical outcome after peptide-based therapeutic immunization for chronic HIV infection.
Kran AM; Sommerfelt MA; Baksaas I; Sørensen B; Kvale D
APMIS; 2012 Mar; 120(3):204-9. PubMed ID: 22339677
[TBL] [Abstract][Full Text] [Related]
24. Predictors for non- and slow progression in human immunodeficiency virus (HIV) type 1 infection: low viral RNA copy numbers in serum and maintenance of high HIV-1 p24-specific but not V3-specific antibody levels.
Hogervorst E; Jurriaans S; de Wolf F; van Wijk A; Wiersma A; Valk M; Roos M; van Gemen B; Coutinho R; Miedema F
J Infect Dis; 1995 Apr; 171(4):811-21. PubMed ID: 7706807
[TBL] [Abstract][Full Text] [Related]
25. Recombinant HIV-1 glycoprotein 120 induces distinct types of delayed hypersensitivity in persons with or without pre-existing immunologic memory.
Hladik F; Bender S; Akridge RE; Hu YX; Galloway C; Francis D; McElrath MJ
J Immunol; 2001 Mar; 166(5):3580-8. PubMed ID: 11207319
[TBL] [Abstract][Full Text] [Related]
26. Vaccination with gp120-depleted HIV-1 plus immunostimulatory CpG oligodeoxynucleotides in incomplete Freund's adjuvant stimulates cellular and humoral immunity in rhesus macaques.
Silvera P; Savary JR; Livingston V; White J; Manson KH; Wyand MH; Salk PL; Moss RB; Lewis MG
Vaccine; 2004 Dec; 23(6):827-39. PubMed ID: 15542208
[TBL] [Abstract][Full Text] [Related]
27. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response.
MacGregor RR; Boyer JD; Ugen KE; Lacy KE; Gluckman SJ; Bagarazzi ML; Chattergoon MA; Baine Y; Higgins TJ; Ciccarelli RB; Coney LR; Ginsberg RS; Weiner DB
J Infect Dis; 1998 Jul; 178(1):92-100. PubMed ID: 9652427
[TBL] [Abstract][Full Text] [Related]
28. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.
Ensoli B; Nchabeleng M; Ensoli F; Tripiciano A; Bellino S; Picconi O; Sgadari C; Longo O; Tavoschi L; Joffe D; Cafaro A; Francavilla V; Moretti S; Pavone Cossut MR; Collacchi B; Arancio A; Paniccia G; Casabianca A; Magnani M; Buttò S; Levendal E; Ndimande JV; Asia B; Pillay Y; Garaci E; Monini P;
Retrovirology; 2016 Jun; 13(1):34. PubMed ID: 27277839
[TBL] [Abstract][Full Text] [Related]
29. Reduced viral burden amongst high responder patients following HIV-1 p24 peptide-based therapeutic immunization.
Kran AM; Sommerfelt MA; Sørensen B; Nyhus J; Baksaas I; Bruun JN; Kvale D
Vaccine; 2005 Jul; 23(31):4011-5. PubMed ID: 15963359
[TBL] [Abstract][Full Text] [Related]
30. The affinity of IgG antibodies to gag p24 and p17 in HIV-1-infected patients correlates with disease progression.
Chargelegue D; Stanley CM; O'Toole CM; Colvin BT; Steward MW
Clin Exp Immunol; 1995 Feb; 99(2):175-81. PubMed ID: 7851008
[TBL] [Abstract][Full Text] [Related]
31. Immunological and virological interactions in patients receiving passive immunotherapy with HIV-1 neutralizing monoclonal antibodies.
Hinkula J; Bratt G; Gilljam G; Nordlund S; Broliden PA; Holmberg V; Olausson-Hansson E; Albert J; Sandström E; Wahren B
J Acquir Immune Defic Syndr (1988); 1994 Sep; 7(9):940-51. PubMed ID: 8051620
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 x 10(6)/L CD4 cell counts: A randomized controlled trial.
Kahn JO; Cherng DW; Mayer K; Murray H; Lagakos S
JAMA; 2000 Nov; 284(17):2193-202. PubMed ID: 11056590
[TBL] [Abstract][Full Text] [Related]
33. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network.
Belshe RB; Graham BS; Keefer MC; Gorse GJ; Wright P; Dolin R; Matthews T; Weinhold K; Bolognesi DP; Sposto R
JAMA; 1994 Aug; 272(6):475-80. PubMed ID: 7913731
[TBL] [Abstract][Full Text] [Related]
34. Autoproliferation in HIV-1-infected patients undergoing active HIV-1-specific immunotherapy.
Trauger RJ; Giermakowska W; Wormsley S; Turner J; Jensen FC; Carlo DJ
Clin Exp Immunol; 1995 Apr; 100(1):7-12. PubMed ID: 7697926
[TBL] [Abstract][Full Text] [Related]
35. Enhancement of HIV type 1 antigen-specific CD4+ T cell memory in subjects with chronic HIV type 1 infection receiving an HIV type 1 immunogen.
Maino VC; Suni MA; Wormsley SB; Carlo DJ; Wallace MR; Moss RB
AIDS Res Hum Retroviruses; 2000 Apr; 16(6):539-47. PubMed ID: 10777144
[TBL] [Abstract][Full Text] [Related]
36. Delayed-type hypersensitivity to recombinant HIV envelope glycoprotein (rgp160) after immunization with homologous antigen.
Katzenstein DA; Kundu S; Spritzler J; Smoller BR; Haszlett P; Valentine F; Merigan TC
J Acquir Immune Defic Syndr; 1999 Dec; 22(4):341-7. PubMed ID: 10634195
[TBL] [Abstract][Full Text] [Related]
37. The effects of an HIV-1 immunogen (Remune) on viral load, CD4 cell counts and HIV-specific immunity in a double-blind, randomized, adjuvant-controlled subset study in HIV infected subjects regardless of concomitant antiviral drugs.
Turner JL; Kostman JR; Aquino A; Wright D; Szabo S; Bidwell R; Goodgame J; Daigle A; Kelley E; Jensen F; Duffy C; Carlo D; Moss RB
HIV Med; 2001 Apr; 2(2):68-77. PubMed ID: 11737381
[TBL] [Abstract][Full Text] [Related]
38. Maternal and newborn immunization with a human immunodeficiency virus-1 immunogen in a rodent model.
Moss RB; Savary JR; Diveley JP; Jensen F; Carlo DJ
Immunology; 2002 Aug; 106(4):549-53. PubMed ID: 12153518
[TBL] [Abstract][Full Text] [Related]
39. In vitro immune function after vaccination with an inactivated, gp120-depleted HIV-1 antigen with immunostimulatory oligodeoxynucleotides.
Moss RB; Diveley J; Jensen F; Carlo DJ
Vaccine; 2000 Jan; 18(11-12):1081-7. PubMed ID: 10590329
[TBL] [Abstract][Full Text] [Related]
40. Immunization with recombinant p17/p24:Ty virus-like particles in human immunodeficiency virus-infected persons.
Veenstra J; Williams IG; Colebunders R; Dorrell L; Tchamouroff SE; Patou G; Lange JM; Weller IV; Goeman J; Uthayakumar S; Gow IR; Weber JN; Coutinho RA
J Infect Dis; 1996 Oct; 174(4):862-6. PubMed ID: 8843231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
